title: Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter.
abstract: Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of the thyroid-specific expression of the human sodium iodide symporter (hNIS). Here, we explore the efficacy of a novel form of gene therapy using prostate-specific membrane antigen (PSMA) promoter-mediated hNIS gene transfer followed by radioiodine administration for the treatment of castration-resistant prostate cancer (CRPC). The androgen-dependent C33 LNCaP cell line and the androgen-independent C81 LNCaP cell line were transfected by adenovirus. PSMA promoter-hNIS (Ad.PSMApro-hNIS) or adenovirus.cytomegalovirus-hNIS containing the cytomegalovirus promoter (Ad.CMV-hNIS) or a control virus. The iodide uptake was measured in vitro. The in vivo iodide uptake by C81 cell xenografts in nude mice injected with an adenovirus carrying the hNIS gene linked to PSMA and the corresponding tumor volume fluctuation were assessed. Iodide accumulation was shown in different LNCaP cell lines after Ad.PSMApro-hNIS and Ad.CMV-hNIS infection, but not in different LNCaP cell lines after adenovirus.cytomegalovirus (Ad.CMV) infection. At each time point, higher iodide uptake was shown in the C81 cells infected with Ad.PSMApro-hNIS than in the C33 cells (P < 0.05). An in vivo animal model showed a significant difference in 131 I radioiodine uptake in the tumors infected with Ad.PSMApro-hNIS, Ad.CMV-hNIS and control virus (P < 0.05) and a maximum reduction of tumor volume in mice infected with Ad.PSMApro-hNIS. These results show prostate-specific expression of the hNIS gene delivered by the PSMA promoter and effective radioiodine therapy of CRPC by the PSMA promoter-driven hNIS transfection.
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Gao
authors.forename: Tie
authors.initials: T
authors.lastname: Zhou
authors.forename: Guang-Hua
authors.initials: GH
authors.lastname: Chen
authors.forename: Chuan-Liang
authors.initials: CL
authors.lastname: Xu
authors.affiliation: Department of Urology, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai 200433, China.
authors.forename: Ye-Lei
authors.initials: YL
authors.lastname: Ding
authors.affiliation: Department of Urology, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai 200433, China.
authors.forename: Ying-Hao
authors.initials: YH
authors.lastname: Sun
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000954:Antigens, Surface / Q000235:genetics*; D045744:Cell Line, Tumor; D015316:Genetic Therapy; D043425:Glutamate Carboxypeptidase II / Q000235:genetics*; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D064129:Prostatic Neoplasms, Castration-Resistant / Q000532:radiotherapy*; D027981:Symporters / Q000235:genetics*; D014162:Transfection; D000099209:Sodium-Iodide Symporters
chemical_list: D000954:Antigens, Surface; D043425:Glutamate Carboxypeptidase II; D007457:Iodine Radioisotopes; D027981:Symporters; D000099209:Sodium-Iodide Symporters; C473848:FOLH1 protein, human